000755887 000__ 04221cam\a2200493Ii\4500
000755887 001__ 755887
000755887 005__ 20230306141818.0
000755887 006__ m\\\\\o\\d\\\\\\\\
000755887 007__ cr\cn\nnnunnun
000755887 008__ 160614s2016\\\\nyua\\\\o\\\\\001\0\eng\d
000755887 019__ $$a951977861
000755887 020__ $$a9783319342115$$q(electronic book)
000755887 020__ $$a3319342118$$q(electronic book)
000755887 020__ $$z9783319342092
000755887 035__ $$aSP(OCoLC)ocn951678372
000755887 035__ $$aSP(OCoLC)951678372$$z(OCoLC)951977861
000755887 040__ $$aN$T$$beng$$erda$$epn$$cN$T$$dIDEBK$$dYDXCP$$dGW5XE$$dN$T$$dAZU$$dEBLCP$$dOCLCF$$dCOO
000755887 049__ $$aISEA
000755887 050_4 $$aRC268.4
000755887 08204 $$a616.99/4$$223
000755887 24500 $$aPI3K-mTOR in cancer and cancer therapy$$h[electronic resource] /$$cNandini Dey, Pradip De, Brian Leyland-Jones, editors.
000755887 264_1 $$aNew York :$$bHumana Press,$$c2016.
000755887 300__ $$a1 online resource (xxiv, 294 pages) :$$bcolor illustrations.
000755887 336__ $$atext$$btxt$$2rdacontent
000755887 337__ $$acomputer$$bc$$2rdamedia
000755887 338__ $$aonline resource$$bcr$$2rdacarrier
000755887 4901_ $$aCancer drug discovery and development,$$x2196-9906
000755887 500__ $$aIncludes index.
000755887 504__ $$aIncludes bibliographical references and index.
000755887 5050_ $$aPI3K-Akt-mTOR Signaling in Cancer and Cancer Therapeutics -- Part 1: PI3K-mTOR Pathway in Cancers -- The mTOR Complexes in Cancer Cell Metabolism -- PI3K-AKT-mTOR Pathway Co-operates with the DNA Damage Repair Pathway: Carcinogenesis in Triple Negative Breast Cancers and Beyond -- The AKT-mTOR Signaling Pathway for Drug Response Prediction and Prognostic Signatures -- Resistance to PI3K Pathway Inhibition -- Part 2: PI3K-mTOR Pathway in Cancer Medicine -- Combination Therapies Targeting the PI3K/AKT/mTOR Pathways -- Phospho-Inositol-3-Kinase Activity and Dysregulation in Pediatric Leukemia and Lymphoma -- HER2 Signaling Network in Advanced Breast Cancer: Opportunities for Combination Therapies -- The PI3K-mTOR Pathway in Prostate Cancer: Biological Significance and Therapeutic Opportunities.
000755887 506__ $$aAccess limited to authorized users.
000755887 520__ $$aIn the post human-genome project era, cancer specific genomic maps are redesigning tumor taxonomy by evolving from histopathology to molecular pathology. The success of a cancer drug today is fundamentally based on the success in identifying target genes that control beneficial pathways. The overwhelming power of genomics and proteomics has enlightened researchers about the fact that the PI3K-mTOR pathway is the most commonly up-regulated signal transduction pathway in various cancers, either by virtue of its activation downstream of many cell surface growth factor receptors or by virtue of its collateral and compensatory circuitry with RAS-MAPK pathway. Oncogenic signaling in the majority of solid tumors is sustained via the PI3K-AKT-mTOR pathway. Because of its prominent role in many cancer types, the PI3K-mTOR pathway has become a major therapeutic target. The volume includes two complementary parts which address the problem of etiology and disease progression and is intended to portray the very basic mechanisms of the PI3K-AKT-mTOR signaling pathway's involvement in various facets of the cancer, including stem cell renewal, cell metabolism, angiogenesis, genetic instability, and drug resistance. Significant progress has been made in recent years elucidating the molecular mechanism of cancer cell proliferation, angiogenesis, and drug-resistance in relation to the PI3K-mTOR pathway and this volume provides an in-depth overview of recent developments made in this area.
000755887 588__ $$aOnline resource; title from PDF title page (SpringerLink, viewed June 20, 2016).
000755887 650_0 $$aCancer$$xMolecular aspects.
000755887 650_0 $$aCancer$$xTreatment.
000755887 7001_ $$aDey, Nandini,$$eeditor.
000755887 7001_ $$aDe, Pradip,$$eeditor.
000755887 7001_ $$aLeyland-Jones, Brian,$$eeditor.
000755887 77608 $$iPrint version:$$aDey, Nandini$$tPI3K-mTOR in Cancer and Cancer Therapy$$dCham : Springer International Publishing,c2016$$z9783319342092
000755887 830_0 $$aCancer drug discovery and development.
000755887 852__ $$bebk
000755887 85640 $$3SpringerLink$$uhttps://univsouthin.idm.oclc.org/login?url=http://link.springer.com/10.1007/978-3-319-34211-5$$zOnline Access$$91397441.1
000755887 909CO $$ooai:library.usi.edu:755887$$pGLOBAL_SET
000755887 980__ $$aEBOOK
000755887 980__ $$aBIB
000755887 982__ $$aEbook
000755887 983__ $$aOnline
000755887 994__ $$a92$$bISE